此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

低组胺改良地中海饮食对多发性硬化症的影响 (HistaMed-MS)

2026年11月14日 更新者:Murat Açık、Firat University

一项关于低组胺改良地中海饮食在多发性硬化症中的随机对照试验:饮食干预对临床发现、血浆组胺和氧化应激的影响

This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS). The study will compare three groups: a low-histamine modified Mediterranean diet, a traditional Mediterranean diet, and a control group without dietary intervention. The main outcomes include clinical measures such as disability status, fatigue, and quality of life, as well as blood markers including plasma histamine, diamine oxidase concentration, total antioxidant capacity, and oxidative stress indicators. The goal is to determine whether reducing dietary histamine within a Mediterranean diet pattern provides additional benefits beyond a traditional Mediterranean diet in improving symptoms and biological markers related to inflammation and oxidative stress in RRMS.

研究概览

详细说明

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Current immunomodulatory treatments have important side effects and do not fully address symptoms or quality of life, highlighting the need for complementary strategies such as targeted dietary interventions. The Mediterranean diet is one of the most promising patterns because of its anti-inflammatory and antioxidant properties and has been associated with reduced fatigue, improved quality of life, and potential benefits on disability in people with MS. However, some components of the traditional Mediterranean diet, such as certain fish, aged cheeses, fermented products, tomatoes, and citrus fruits, are relatively high in histamine. Histamine is a biogenic amine that may influence neuroinflammation and blood-brain barrier permeability, and diets that lower histamine intake have shown benefits in conditions like migraine and gastrointestinal dysfunction, which are common in MS. This study was designed to explore whether a low histamine-based modified Mediterranean diet can optimize the benefits of the Mediterranean pattern in relapsing-remitting MS (RRMS).

The trial is a three-arm, parallel-group, randomized controlled clinical study in adults with RRMS. Participants are randomly assigned to one of three groups: (1) a low histamine-based modified Mediterranean diet, which maintains the core principles of the Mediterranean pattern while restricting foods known to be high in histamine or to promote histamine release; (2) a traditional Mediterranean diet without specific histamine-related restrictions; or (3) a control group that does not receive a structured dietary intervention. The intervention focuses on high intake of fresh vegetables and fruits, legumes, whole grains, olive oil, and appropriate fish options, while the modified diet group additionally limits aged cheeses, processed meats, fermented foods, vinegar, fish and seafood, and selected vegetables and fruits that are high in histamine. This design allows direct comparison of no diet intervention, a well-established Mediterranean pattern, and a targeted low-histamine modification of that pattern.

Clinical outcomes include disability status assessed by the Expanded Disability Status Scale (EDSS), fatigue measured with the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), and health-related quality of life evaluated with the Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire. To investigate potential mechanisms, blood biomarkers are measured, including serum total antioxidant capacity, oxidative stress markers (for example malondialdehyde), plasma histamine levels, and plasma concentration of diamine oxidase (DAO), an enzyme that metabolizes histamine. The primary hypotheses are that both Mediterranean diet interventions will improve fatigue, quality of life, and oxidative stress parameters compared with the control group, and that the low histamine-based modified Mediterranean diet will provide the greatest benefits, particularly in reducing plasma histamine, increasing DAO concentration, and alleviating fatigue and disability scores in RRMS. If confirmed, the findings could support a more targeted dietary approach as a complementary medical nutrition therapy for MS and provide a basis for future interventional studies on histamine metabolism, oxidative stress, and diet in this population.

研究类型

介入性

注册 (实际的)

57

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Elâzığ
      • Elâzığ、Elâzığ、土耳其(türkiye)、23119
        • Firat University Hospital, Neurology Clinic

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

19年 至 64年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 19 to 64 years.
  • Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to 2017 McDonald criteria.
  • EDSS score < 4.5.
  • On stable immunomodulatory treatment for at least 6 months.
  • Body mass index (BMI) 18.5-29.9 kg/m².

Exclusion Criteria:

  • Relapse and/or corticosteroid treatment within the last 1 month.
  • Clinically significant metabolic, progressive, or malignant disease.
  • Use of at least 1 g/day fish oil supplementation.
  • Insulin-dependent diabetes mellitus.
  • Participation in another interventional study.
  • Weight loss or gain ≥ 5% in the last 6 months.
  • Following a weight-loss diet in the last 2 months.
  • Use of oral anticoagulant therapy.
  • Presence of eating disorders, alcohol or substance dependence.
  • Pregnancy or breastfeeding.
  • Inability to comply with dietary intervention according to weekly follow-up assessments.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Low Histamine-Based Modified Mediterranean Diet

Participants receive a low histamine-based modified Mediterranean diet with restriction of high-histamine and histamine-releasing foods while preserving core Mediterranean diet principles.

Structured dietary program based on the Mediterranean diet with restriction of high-histamine and histamine-releasing foods (e.g., aged cheeses, processed meats, fish and seafood, fermented products, vinegar, some fruits and vegetables); fish is replaced with poultry.

有源比较器:Traditional Mediterranean Diet

Participants receive a traditional Mediterranean diet without specific histamine-related restrictions.

Structured dietary program following a traditional Mediterranean diet rich in vegetables, fruits, whole grains, legumes, olive oil, and fish, without specific histamine-related restrictions.

无干预:Control (Usual Diet)

Participants continue their usual diet and do not receive a structured dietary intervention.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in neurological fatigue (Neurological Fatigue Index for Multiple Sclerosis [NFI-MS] subscale scores; ranges: physical fatigue 0-24, cognitive fatigue 0-12, diurnal sleep 0-18, nocturnal sleep 0-15; higher scores indicate greater fatigue)
大体时间:Baseline, week 6 and week 12

Fatigue will be assessed using the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), a 23-item self-reported questionnaire with four subscales: physical fatigue (8 items), cognitive fatigue (4 items), relief by diurnal sleep or rest (6 items), and abnormal nocturnal sleep and sleepiness (5 items). Items are rated from 0 to 3, each subscale is scored separately (no total score is calculated), and higher scores indicate greater fatigue. The outcome is the change in each subscale score from baseline to week 12 across the three study groups.

Baseline, week 6 and week 12
Change in plasma histamine concentration
大体时间:From baseline to 12 weeks

Plasma histamine will be measured in fasting EDTA plasma by competitive ELISA. The outcome is the change in plasma histamine concentration (ng/mL) between baseline and the end of the intervention.

From baseline to 12 weeks
Change in plasma diamine oxidase (DAO) concentration
大体时间:From baseline to 12 weeks

Plasma diamine oxidase (DAO), a key enzyme of histamine metabolism, will be measured in fasting EDTA plasma by sandwich ELISA. The outcome is the change in plasma DAO concentration (ng/mL) between baseline and the end of the intervention.

From baseline to 12 weeks

次要结果测量

结果测量
措施说明
大体时间
Change in disability status (Expanded Disability Status Scale [EDSS]; scale range: 0-10; higher scores indicate greater disability)
大体时间:From baseline to 12 weeks

Disability will be assessed using the Expanded Disability Status Scale (EDSS). The outcome is the change in EDSS score from baseline to the end of the intervention.

From baseline to 12 weeks
Change in health-related quality of life (Multiple Sclerosis Quality of Life-54 [MSQOL-54]; scale range: 0-100 for subscale and composite scores; higher scores indicate better health-related quality of life)
大体时间:From baseline to 12 weeks

Health-related quality of life will be assessed using the MSQOL-54 questionnaire. The outcome is the change in MSQOL-54 scores from baseline to the end of the intervention.

From baseline to 12 weeks
Change in serum total antioxidant capacity
大体时间:From baseline to 12 weeks

Serum total antioxidant capacity will be measured to evaluate antioxidant status. The outcome is the change in serum total antioxidant capacity between baseline and the end of the intervention.

From baseline to 12 weeks
Change in oxidative stress markers (e.g., malondialdehyde)
大体时间:From baseline to 12 weeks

Oxidative stress will be assessed using markers such as malondialdehyde (MDA). The outcome is the change in oxidative stress markers between baseline and the end of the intervention.

From baseline to 12 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Murat Gönen, Prof. Dr.、Firat University Faculty of Medicine

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年6月15日

初级完成 (实际的)

2025年3月10日

研究完成 (实际的)

2025年6月10日

研究注册日期

首次提交

2026年1月22日

首先提交符合 QC 标准的

2026年3月26日

首次发布 (实际的)

2026年3月30日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月14日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data underlying the results reported in the publication will be shared, together with the data dictionary.

IPD 共享时间框架

Beginning after publication of the main results.

IPD 共享访问标准

Available from the corresponding author upon reasonable request, subject to approval by the institutional ethics committee.

IPD 共享支持信息类型

  • 分析代码

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅